PepGen opened at $5.26, in line with its previous close of $5.26. In the last trading session, the stock traded between $4.84 and $5.35. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in PepGen is now worth
$ 39.29
Resulting in a loss of
$ 60.71 (60.71%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
83.33%
Hold
16.67%
Sell
0%
Markets Today
Today's Change
$-0.20 (-3.73%)
Day High
$5.35
Day Low
$4.84
Day Open
$5.26
Prev Close
$5.26
Volume
1,12,23,072
1W Return
107.29%
1M Return
102.97%
3M Return
74.92%
6M Return
197.88%
1Y Return
8.90%
Fundamentals
Market Cap ($ Mn)
351
PE Ratio
-
PB Ratio
1.78
PEG Ratio
-
ROE
-75.70%
ROCE
-70.32%
EPS (TTM)
$-0.28
Investment Returns
1 Week
107.29%
1 Month
102.97%
3 Months
74.92%
6 Months
197.88%
9 Months
-11.62%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
12Nov
PepGen prices $125 million public offering at $5.00 per share
PepGen priced a public offering of 25 million shares at $5.00 per share. Gross proceeds expected to reach $125 million before fees. Underwriters hold a 30-day option for up to 3.75 million additional shares. Net proceeds will fund clinical development of PGN-EDODM1.
Today
11Nov
Wedbush raises PepGen price target to $10, maintains outperform
Wedbush maintains Outperform rating on PepGen. Price target raised from $4 to $10. Analyst Laura Chico issued the rating update.
Yesterday
11Nov
PepGen shares double on positive Phase 2 DM1 trial results
PepGen shares rose 111.30% to $5.05 following positive Phase 2 trial data. Mean muscle splicing correction reached 46.5% at Week 13 versus 6.8% in placebo. Four of six participants achieved more than 50% splicing correction. Video Hand Opening Time improved by 52.7% compared to 0.2% in placebo. Next data readout for 12.5 mg/kg cohort expected in first half of 2027.
2 days ago
9Sep
HC Wainwright reiterates Buy on PepGen, keeps $20 target
HC Wainwright & Co. reiterates a Buy rating on PepGen. Analyst Ananda Ghosh maintains the price target at $20. The firm continues to recommend holding or accumulating shares.
2mo ago
16Jun
Craig-Hallum initiates coverage on PepGen with Buy rating, $11 target
Craig-Hallum analyst Adam Vogel initiated coverage on PepGen with a Buy rating and a $11 price target. The rating underscores a positive outlook for the NASDAQ-listed biotech company.
